ABEO
Abeona Therapeutics Inc.
Abeona Therapeutics (ABEO) Q2 2026 earnings
Published Aug 13, 2026
AI summary
- Revenue $11.4M, up 2745% from $400K a year ago.
- GAAP EPS −$0.35 missed the −$0.24 consensus by $0.10, down from $1.71 a year ago.
- Abeona reported Q2 2026 revenue of $11.4 million, driven by the commercial launch of ZEVASKYN.
- The company treated five patients with ZEVASKYN during the second quarter.
- Net loss for the quarter was $20.2 million, or $0.35 per diluted share.
Results vs analyst consensus
Revenue
Reported
$11.4M
Consensus not captured before release
Not verified against provider data.
+2745% YoY
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$0.35
Consensus −$0.24
Missed by $0.10GAAP EPS: −$0.35
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- Revenue was not recognized for one patient treatment due to manufacturing yield issues.
- The company reported a net loss and continues to invest heavily in R&D and commercial operations.
Read original report
Source: Abeona Therapeutics Inc. press release · SEC Form 8-K exhibit 99.1